Allogeneic bone marrow-derived mesenchymal stromal cell therapy （Orbsen Therapeutics）

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAllogeneic bone marrow-derived mesenchymal stromal cell therapy （Orbsen Therapeutics）

Drug Alias NameNEPHSTROMORBCEL-M

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsDiabetic Nephropathies

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesOrbsen Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesOrbsen Therapeutics

Inactive CompaniesN/A

Active IndicationsDiabetic Nephropathies

Inactive IndicationsN/A

Other Information

ATC CodeN/A